Navigation Links
Rheumatoid in Biological Technology

Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA)

... advice and information for adults living with rheumatoid arthritis (RA). Deborah Norville and expert ... I was 10 years old, my mother was diagnosed with rheumatoid arthritis, and my family struggled as my mother's ... in the taping of New Way RA .) About rheumatoid Arthritis ...

Schering-Plough Reports Financial Results for 2009 Second Quarter

... as a once-monthly, subcutaneous therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing ... in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic ...

New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives

... Patients Surveyed Experience Daily Pain From rheumatoid Arthritis Despite Current Treatment; Findings ... 10 /PRNewswire-FirstCall/ -- Results from the rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey of more than 500 rheumatoid arthritis (RA) patients throughout Europe and ...

Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

... potential cost effective approach for rheumatoid arthritis TSX Exchange Symbol: RVX ... effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's R&D team is ... markets. For example, a small molecular drug for rheumatoid arthritis is estimated to range in price from US ...

Rigel Announces First Quarter 2009 Financial Results

... Company's two Phase 2b clinical trials of R788 in rheumatoid arthritis (TASKi2 and TASKi3) . As a result of ... over 670 additional patients studied with R788 in rheumatoid arthritis to the 189 patients studied from our ... in inflammatory/autoimmune diseases such as rheumatoid arthritis thrombocytopenia and asthma, as well as ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... Technology also has potential to fight cancer, rheumatoid arthritis, as well as enhance the effectiveness ... against HIV, and promote immunotherapy for rheumatoid arthritis. The L.E.A.P.S. technology combines a ... L.E.A.P.S. vaccine incorporating a peptide from a rheumatoid arthritis disease protein, was shown to curtail ...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis ... and symptoms of RA, PsA and AS. About rheumatoid Arthritis RA is a chronic and debilitating ... the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ...

Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring

... 2010 -- Announce TRU-015 Phase 2b (15002) rheumatoid arthritis re-treatment data at the annual ... (ACR) -- Announce TRU-015 Phase 2b (2203) rheumatoid arthritis trial data by end of Q4 2009 (currently ... by Wyeth) -- Announce SBI-087 Phase 1 rheumatoid arthritis trial data by end of Q4 2009 (currently ...

Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models

... for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the ... of inflammatory autoimmune diseases such as rheumatoid arthritis and identify 2ME2 as a disease ... disease progression in preclinical models of rheumatoid arthritis. Furthermore, these results indicate ...

Rigel Announces Third Quarter 2008 Financial Results and Clinical Update

... "Data from our Phase 2a clinical trial of R788 in rheumatoid arthritis was recently presented by the principal ... Update R788 Rigel expects that R788 for rheumatoid arthritis will continue to be the primary ... Two Phase 2b clinical trials are ongoing in rheumatoid arthritis, TASKi2 and TASKi3. Rigel expects ...

Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis

... in patients with active moderate to severe rheumatoid arthritis (RA) were presented at the American ... of hepatitis B and other serious events. About rheumatoid Arthritis RA is a chronic and debilitating ... innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... of new treatments for diseases such as lupus, rheumatoid arthritis, and myositis" MedImmune programs ... a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha ... aggregates called follicles. In patients with rheumatoid arthritis the levels of CXCL13 are elevated ...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

... of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment ACTEMRA(R) (tocilizumab) ... Improves Outcomes in Patients with rheumatoid Arthritis Who Have Inadequate Response to TNF ... Methotrexate Monotherapy in Patients with rheumatoid Arthritis" (Presenter: Graeme Jones, M.D.) ...

EntreMed to Present at BioPartnering Europe Conference

... disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical ... has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and ... treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed ...

Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research

... as an effective therapeutic target for rheumatoid arthritis and other chronic ... trials revealed rapid and dramatic improvement of rheumatoid disease activity with anti-TNF ... defining TNF as a good therapeutic target for rheumatoid arthritis has subsequently led to TNF blockade in ...

Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis

... improvements in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function ... as the First-line Option in the treatment of rheumatoid arthritis of Early onset (GO-BEFORE), MTX-nave ... depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in ...

Schering-Plough Reports Financial Results for First Quarter of 2008

... in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic ... subcutaneous treatment for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing ...

Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... experience golimumab as a therapeutic option for rheumatoid arthritis, psoriatic arthritis and ankylosing ... of more than 1,400 adults with moderate to severe rheumatoid arthritis will be presented at the ... Rheumatism Annual Congress in June 2008. About rheumatoid Arthritis ...

EntreMed Announces 2008 Corporate and Clinical Program Priorities

... NCD. -- EntreMed plans to move 2ME2 forward in rheumatoid arthritis based on the knowledge gained from ... has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a ... treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed ...

FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis

... for the treatment of adult patients with active rheumatoid arthritis (RA). Cimzia(R) is an investigational ... biologic therapy available for the treatment of rheumatoid arthritis. "As a new anti-TNF, we believe that ... and it was launched in January 2008. About rheumatoid Arthritis RA is a progressive autoimmune ...

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

... of chronic inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ... for patients being treated for active early rheumatoid arthritis with Enbrel plus methotrexate compared ... These results were from the first major early rheumatoid arthritis clinical trial of a biologic to use ...

REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide

... followed by additional indications, such as rheumatoid arthritis. "Rheumatoid arthritis derailed my ... (adult and pediatric), ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic ... of patients with inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, ...

Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting

... its late-breaking abstract for TRU-015 for rheumatoid arthritis (RA), have been accepted for ... Friday, Nov. 9, 2007 Poster L7: TRU-015 Improves rheumatoid Arthritis Disease Activity in a Randomized, ... a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered ...

Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA

... Administration of Prednisone in rheumatoid Arthritis), Nitec submitted a dossier for ... "The new Lodotra trial is highly relevant for rheumatoid arthritis patients. Lodotra reduces IL-6 levels ... circadian cytokine modulator for the treatment of rheumatoid arthritis (RA). Nitec was originally founded ...

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

... due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that ... of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of ...

Lycera Closes $36 Million Series A Financing

... novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has received $10 million as a ... for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease and transplant ...

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab

... across many stages of cancer. Denosumab is also being investigated in rheumatoid arthritis. Osteoporosis: Impact and Prevalence Often referred to ... of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of ...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds ... -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

... cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds ... - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

... cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds ... -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

EntreMed Reports Third Quarter 2008 Financial Results

... cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds ... -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study

... program for golimumab, including data from five pivotal Phase 3 trials in rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis. About ... has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative ...

Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis

... continues to produce persistent responses and significant improvements in rheumatoid arthritis (RA) signs and symptoms based on American College of ... 240 patients at the time of this evaluation, of which 204 patients were rheumatoid factor (RF) positive. Under the study protocol, the efficacy endpoint was ...

WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL

... of G-CSF or its receptor could ameliorate inflammatory conditions such as rheumatoid arthritis. Under the terms of the restructure, CSL will now take full ... diseases, including diabetes, multiple sclerosis, coeliac disease and rheumatoid arthritis. Over many decades, advances and discoveries in these areas have ...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

... cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds ... -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market

... cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds ... -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

... offer a different approach to therapeutic intervention in diseases such as rheumatoid arthritis or multiple sclerosis. Under the agreement GSK has exclusive ... as PI3Kg and d, Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and ...

Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug

... of inflammation caused by chronic conditions, such as osteoarthritis and rheumatoid arthritis. Despite its considerable efficacy and its good cardiovascular ... are associated with excessive inflammation, including osteoarthritis and rheumatoid arthritis. For more information on Logical Therapeutics, visit the ...

EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development

... company. With three oncology products already in the clinic and a rheumatoid arthritis product entering the clinic, the Company's clinical pipeline is ... -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the ...

Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research

... condition. Clinical trials revealed rapid and dramatic improvement of rheumatoid disease activity with anti-TNF therapy, which led to development of ... messenger molecule, TNF, was an effective target for treatment not only in rheumatoid arthritis but also other chronic inflammatory conditions, such as ...
Other Contents
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... in about one per eight hundred births, Down syndrome ... genetic cause of intellectual disability. It results from a ... third copy of chromosome 21 (1% of the human ... team in the Department of Genetic Medicine and Development ... published in Nature , shed light on how ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work has transformed ... a Fellow of the European Academy of Cancer Sciences., ... independent advisory body of highly distinguished oncologists and cancer ... caused by cancer in Europe. , Professor Johnston, whose ... move from the bottom of the UK league table ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... that fertility treatments are the leading cause of increases ... risk of premature birth, these results are not inevitable, ... . The article identifies six changes in policy ... births and prematurity, including expanding insurance coverage for in ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
Other TagsOther Tags